Sigurd Friedwald Lax

Sigurd Friedwald Lax

Auto-generated profile, based on publicly available information

Sigurd Friedwald Lax

Klinisches Institut für Pathologie und Molekularpathologie, Johannes Kepler Universität Linz, Linz, Österreich

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2020 in Virchows Archiv
Verified
Journal Article
Open access
PDF file
Kristijan SkokKristijan Skok
Kristijan Skok
ESEvelyn Stelzl
Evelyn Stelzl
MTMichael Trauner
Michael Trauner
HKHarald H. Kessler
Harald H. Kessler
SLSigurd F. Lax
Sigurd F. Lax
The persistence of SARS-CoV-2 after death of infected individuals is unclear. The aim of this study was to investigate the presence of SARS-CoV-2 RNA in different organs in correlation with tissue damage and post-mortem viral dynamics in COVID-19 deceased. Twenty-eight patients (17 males, 11 females; age 66–96 years; mean 82.9, median 82.5 years) diagnosed with COVID-19 were studied. Swabs were taken post-mortem during autopsy (N = 19) from the throat, both lungs, intestine, gallbladder, and brain or without autopsy (N = 9) only from the throat. Selective amplification of target nucleic acid from the samples was achieved by using primers for ORF1a/b non-structural region and the structural protein envelope E-gene of the virus. The results of 125 post-mortem and 47 ante-mortem swabs were presented as cycle threshold (Ct) values and categorized as strong, moderate, and weak. Viral RNA was detected more frequently in the lungs and throat than in the intestine. Blood, bile, and the brain were negative. Consecutive throat swabs were positive up to 128 h after death without significant increase of Ct values. All lungs showed diffuse alveolar damage, thrombosis, and infarction and less frequently bronchopneumonia irrespective of Ct values. In 30% the intestine revealed focal ischemic changes. Nucleocapsid protein of SARS-CoV-2 was detected by immunohistochemistry in bronchial and intestinal epithelium, bronchial glands, and pneumocytes. In conclusion, viral RNA is still present several days after death, most frequently in the respiratory tract and associated with severe and fatal organ damage. Potential infectivity cannot be ruled out post-mortem.

2 December 2016
Verified
Book Chapter
Closed access
PDF file
SLSigurd F. Lax
Sigurd F. Lax

29 September 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AJAmy Jamieson
Amy Jamieson
LVLisa Vermij
Lisa Vermij
CKClaire Kramer
Claire Kramer
JJJan Jobsen
Jan Jobsen
IJIna Jürgemlienk-Schulz
Ina Jürgemlienk-Schulz
TBTjalling Bosse
Tjalling Bosse
Purpose: The clinical significance of the p53-abnormal (p53abn) molecular subtype in stage I low-grade endometrioid endometrial carcinoma (EEC) is debated. We aimed to review pathologic and molecular characteristics, and outcomes of stage I low-grade p53abn EEC in a large international cohort. Experimental Design: Previously diagnosed stage I p53abn EC (POLE–wild-type, mismatch repair–proficient) low-grade EEC from Canadian retrospective cohorts and PORTEC-1&2 trials were included. Pathology review was performed by six expert gynecologic pathologists blinded to p53 status. IHC profiling, next-generation sequencing, and shallow whole-genome sequencing was performed. Kaplan–Meier method was used for survival analysis. Results: We identified 55 stage I p53abn low-grade EEC among 3,387 cases (2.5%). On pathology review, 17 cases (31%) were not diagnosed as low-grade EEC by any pathologists, whereas 26 cases (47%) were diagnosed as low-grade EEC by at least three pathologists. The IHC and molecular profile of the latter cases were consistent with low-grade EEC morphology (ER/PR positivity, patchy p16 expression, PIK3CA and PTEN mutations) but they also showed features of p53abn EC (TP53 mutations, many copy-number alterations). These cases had a clinically relevant risk of disease recurrence (5-year recurrence-free survival 77%), with pelvic and/or distant recurrences observed in 12% of the patients. Conclusions: A subset of p53abn EC is morphologically low-grade EEC and exhibit genomic instability. Even for stage I disease, p53abn low-grade EEC are at substantial risk of disease recurrence. These findings highlight the clinical relevance of universal p53-testing, even in low-grade EEC, to identify women at increased risk of recurrence.

1 January 2021 in Pathology - Research and Practice
Verified
Journal Article
Closed access
Kristijan SkokKristijan Skok
Kristijan Skok
KVKlaus Vander
Klaus Vander
LSLisa Setaffy
Lisa Setaffy
HKHarald H. Kessler
Harald H. Kessler
SAStephan W. Aberle
Stephan W. Aberle
SLSigurd F. Lax
Sigurd F. Lax

1 February 2017 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
FGFriederike Grevenkamp
Friederike Grevenkamp
FKFelix Kommoss
Felix Kommoss
FKFriedrich Kommoss
Friedrich Kommoss
SLSigurd Lax
Sigurd Lax
Falko FendFalko Fend
Falko Fend
SKStefan Kommoss
Stefan Kommoss

13 November 2020 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
TMTina Moser
Tina Moser
JWJulie Waldispuehl-Geigl
Julie Waldispuehl-Geigl
JBJelena Belic
Jelena Belic
SWSabrina Weber
Sabrina Weber
QZQing Zhou
Qing Zhou
MSMichael R. Speicher
Michael R. Speicher
We addressed a significant unknown feature of circulating tumor DNA (ctDNA), i.e., how ctDNA levels change during chemotherapy, by serially monitoring ctDNA in patients with colorectal cancer during the 48-h application of FOLFOX. Surprisingly, we did not observe a spike in ctDNA as a sign of a responsive tumor, but instead ctDNA levels initially decreased and remained low in patients with stable disease or partial response. Our observations reveal further insights into cell destruction during chemotherapy with important implications for the management of patients.